Mosaic chromosomal alterations in blood are associated with an increased risk of Alzheimer’s disease

The Main section reports microglia-annotated brain cells carrying the same mosaic chromosomal alterations as cells in blood, supporting the presence of peripheral somatic alterations in that cell population. It does not establish that these cells are brain-resident microglia: the authors say the finding raises the possibility that blood-derived monocytes entered the brain. (LLM, conf=0.87)

The Main section reports contrasting findings: an earlier multicohort study found CHIP protective against Alzheimer’s disease, whereas this paper finds CHIP associated with increased risk. It also proposes a possible microglial mechanism and analyzes ADSP data. It does not establish that this mechanism explains differences across epidemiological studies, particularly studies using shared ADSP cohorts; that framework is the citing authors’ interpretation. (LLM, conf=0.82)

The Main section reports that Alzheimer’s disease risk associations differ by mCA type and chromosomal location, supporting the idea that genetic features matter. But the paper measures associations with Alzheimer’s disease, not whether the genetic architecture of a clonal expansion determines its impact on the brain; the Main section also says a causal relationship and the biological relevance of the brain-cell findings require further study. No page numbers are available in our copy. (LLM, conf=0.82)

The Methods section (page unavailable) confirms that this paper analyzes the ADSP release R4 cohort. The Main section reports an increased AD risk associated with CHIP in its data and contrasts this with a previously reported protective effect, but it does not identify three independent analytical frameworks applied to the same ADSP cohort or compare their results. (LLM, conf=0.82)

Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

The Main section (page unavailable) reports differing associations for CHIP and other forms of clonal hematopoiesis with Alzheimer’s disease. It also finds that mCA-associated risk varies by APOE genotype and number of mCAs. Those findings lend partial support to the proposed role of genetic background and burden, but the paper does not establish that gene-specific CHIP effects or neurovascular integrity determine whether CHIP-derived brain immune cells are protective or pathogenic. (LLM, conf=0.82)

The Abstract and Main section report an association between autosomal mCAs in blood and increased AD risk, and identify brain microglia-annotated cells carrying the same alterations. They suggest a possible effect on local immune response, but do not establish a shared vascular mechanism. The Main section also cautions that contamination by circulating blood cells cannot be ruled out, so the finding does not establish that the altered cells are brain-resident microglia. (LLM, conf=0.87)

The Main section reports an association between blood mCAs and Alzheimer’s disease and notes a previously reported association between LOY and Alzheimer’s disease. It links clonal hematopoiesis broadly—not mCAs or LOY specifically—to cardiovascular disease, and does not address stroke risk. The evidence supports the Alzheimer’s component, but not the full set of associations claimed. (LLM, conf=0.87)

The Main section reports mCAs in microglia-annotated cells from brain single-nucleus data, supporting identification in cells classified as microglia. It does not establish that those cells were brain-resident microglia: the authors suggest they may derive from blood monocytes and say contamination by circulating blood cells cannot be ruled out. Page numbers are not provided in our copy. (LLM, conf=0.85)

The Main section reports the same blood mosaic chromosomal alterations (mCAs) in microglia-annotated cells and a correlation in their cell fractions in the primary dataset, but not in the replication dataset. It attributes the finding about CHIP mutations to a previous study; its own correlated finding concerns mCAs, not CHIP-associated mutations. The limitations section also says circulating-blood-cell contamination cannot be ruled out, so residence in brain microglia is not established, and the cross-sectional results do not show fluctuation over time. (LLM, conf=0.88)

The Main section reports that blood mCAs and CHIP were independently associated with Alzheimer’s disease, and suggests that mCA-bearing cells may influence the brain’s local immune response. It also notes a general link between clonal hematopoiesis and cardiovascular disease. It does not establish that distinct forms converge on vascular and inflammatory pathways or that those pathways critically shape dementia phenotypes. (LLM, conf=0.85)

The Main section (page not provided) finds blood-associated chromosomal alterations in microglia-annotated brain cells and enrichment of those cells in a redox-related microglial state, supporting their presence in the brain’s disease-relevant cellular landscape. It does not show that the clones outcompete wild-type cells under pathological conditions. (LLM, conf=0.84)